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Introduction
Gynecological tumors, including endometrial, cervical 
and ovarian cancer, have increased in incidence over time. 
Accurate diagnosis and proper monitoring of disease still 
represent the primary target for a successful treatment 
in this group of patients. Currently a multimodal 
approach, combining the evaluation of serum tumor 
biomarkers with imaging techniques, seems the best 
strategy for assessing tumor presence, recurrence, 
and/or the response to treatment in female cancer patients 
(Ferlay et al., 2015). Currently Oncology research is 
directed to the development of noninvasive methods 
to detect and monitor tumors and, in the last years, 
knowledge about cancer biomarkers has considerably 
increased (Wagner et al., 2012). Great attention has been 
paid to identify biological markers to be used as indicators 
of disease activity but also as prognostic and predictive 
factors of survival, recurrence, and treatment response 
in female patients (Binder et al., 2015). In addition, in the 
last few years there has been an important development 
of imaging techniques which has led to a significant 
improvement in tumor staging, monitoring and early 
detection of disease relapses. 
 The final goal is to achieve a more personalized 
management based not only on tumor stage but also on 
the molecular tumor features, to improve patients care 
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combining information provided by imaging and tumor 
markers.
The association of tumor markers assessment with 
different imaging techniques can lead to several advantage 
allowing to localize the sites of the primary or secondary 
lesions, while tumor markers alone provide only a general 
indication of disease presence and in addition to confirm 
disease relapses, possibly before the related clinical 
symptoms. 
In this review we provide an overview of the 
application of biomarkers combined with novel imaging 
methods and highlight their roles in female cancer 
diagnosis and follow-up. 
Endometrial Cancer
Endometrial cancer is the most common gynecologic 
malignancy in Western countries, with an estimated 
annually incidence of 25.1 new cases per 100. 000 women 
(Siegel et al., 2015).
Endomet r i a l  cance r  i s  more  f r equen t  in 
postmenopausal women, and is often associated with 
obesity, nulliparity, anovulation, diabetes and hypertension 
(Soliman et al., 2005). 
Thanks to the early symptoms (about 90% 
of patients experience abnormal uterine bleeding and 
vaginal discharge) , diagnosis is often made at early 
stage (FIGO stage I or II ), with tumor still confined to 
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the uterine corpus in around 75 % of cases. The 5-year 
overall survival is estimated around 80 % but it varies 
for different histological subtypes and tumor stages 
(Creasman et al., 2006).
However, after primary surgery, around 15–20 % of 
these tumors recur in the vagina/pelvis or at distant sites .In 
the metastatic disease, the prognosis is poor with reported 
median survival of only 7–12 month (Oza et al., 2011).
Materials and Methods
Endometrial cancer imaging
Modern imaging tools play an important role in the 
preoperative assessment of disease extent allowing the 
proper therapeutic approach for each patient, but also in 
the post-operative setting, for the early detection of tumor 
relapses. The clinical challenge is to select patients with 
high risk of relapses, who undergo to more extensive 
surgery ,avoiding overtreatment in low-risk patients. 
Ultrasound examination (US) with endovaginal 
approach (TVU) is the first tool of investigation to 
evaluate the endometrial thickening and to select the 
patients undergoing to biopsy. Ortoft et al. found that the 
combination of the preoperative biopsy with ultrasound 
achieved an accuracy of about 72–83 % in the diagnosis 
of high-risk endometrial cancer (Ortoft et al., 2013).
Several Authors validated the high diagnostic 
performance of TVU for the local staging and particularly 
to assess the degree of myometrial infiltration (reported 
Sensitivity 71–85 %, Specificity 72–84 %, Accuracy 
92–94 %), to evaluate the extension to cervical region 
(Sensitivity 72–90 %, Specificitiy 29–93 % and Accuracy 
78–92 %) and in assessing invasion of the serosa 
(Sensitivitity 67%, Specificity 95% and Accuracy 95%) 
(Alcazar et al., 2015; Fischerova et al., 2014). 
More recently the employment of three-dimensional 
(3D) ultrasound technology has been introduced in the 
clinical practice allowing to acquire images of  an entire 
volume from an organ or tissue of interest that may be 
reconstructed in different planes (Ong et al., 2016). 
Alcazar et al., (2009) in their series of 96 patients 
reported  a good diagnostic values of 3DUS (sensitivity 
93 %, specificity 82% and accuracy 85 % ) in detecting 
myometrial invasion.
Magnetic Resonance Imaging (MRI) is considered 
the best method to investigate pelvic female thanks to the 
multi-parametric capabilities of the method. 
In the preoperative staging of endometrial cancer 
,particularly for the assessment of loco-regional disease 
spread, MRI allows to detect deep myometrial invasion 
(Se 33–100 % , Spe 44–100 %, Accuracy 58–100 %) 
cervical stroma invasion (Se 33–69 % ,Spe 82–96 %, 
Accuracy 46–89 %) and metastatic lymph nodes (Se 17–80 
% Spec 88–100 %, Accuracy 83–93 %.) (Haldorsen et al., 
2012a; Haldorsen et al., 2012b; Rechichi et al., 2010).
Contrast-Enhancement Multi Detector Computed 
Tomography (CE-MDCT) is widely employed 
preoperatively for the detection of lymph node 
metastases and distant spread in endometrial cancer 
(Pecorelli et al., 2009).
An important challenge is represented by the lymph 
nodes involvement. The ability to correctly identify 
metastatic lymph nodes depends on  lymph node size; in 
fact sensitivity varies with nodes diameter ( 100, 67, and 13 
% in metastatic nodes ≥10, 5–9, and ≤4 mm, respectively).
Positron Emission Tomography-CT (PET-CT) is 
a valid diagnostic tool in this field combining two imaging 
methods and visualizing both morphologic and metabolic 
tumor characteristics at the same time and showing high 
values of sensitivity, specificity, PPV, NPV, and accuracy 
in predicting lymph node metastases (74%, 93%, 59%, 
96%, and 91% respectively) (Antonsen et al., 2013; 
Kitajima et al., 2015). 
The imaging follow-up of patients treated for 
endometrial cancer is still controversial. Most relapses 
tend to occur in high risk patients within 3 years, the 
commonest sites being lymph nodes and vaginal vault 
(Sohaib et al., 2007). 
The most appropriate follow-up strategy is likely one 
based upon the risk of recurrence and the natural history 
of the disease. 
US and MRI are usually employed to local tumor relapse 
evaluation while MDCT is essential for the assessment of 
lymph-node status and distance metastasis with an overall 
accuracy of 92%  
PET with contrast-enhanced CT is an accurate imaging 
modality for the assessment of uterine cancer recurrence 
and can also change the treatment planning by localizing 
the recurrent lesions.
A study showed that in the detection of recurrence 
FDG-PET, implemented by CT and/or MRI, performed 
better (sensitivity 100%, specificity 88.2%, and accuracy 
93.3%) than CT and/or MRI alone (sensitivity 84.6%, 
specificity 85.7%, and accuracy 85%) (Kitajima et al., 
2010; Park et al., 2008).
Results
Endometrial cancer biomarkers
The use of tumor markers in the diagnosis of 
endometrial cancer is limited by their low specificity. In the 
last years, many research group performed various studies 
aiming to evaluate the diagnostic performance of serum 
tumor biomarkers and to find novel neoplastic indicators 
for the management of endometrial cancer .
CA125 is routinely evaluated at the diagnosis and 
follow-up of endometrial cancer. Elevated serum levels 
of CA125 are associated with some clinicopathologic 
characteristics (local tumor spread, enlarged lymph-nodes, 
carcinomatosis implants and metastases) and poor 
prognosis for this malignancy (Chung et al., 2006). 
However, in the early or very early stages of the disease the 
sensitivity of CA125 is poor, therefore the measurement of 
CA125 for endometrial cancer diagnosis is recommended 
in advanced disease (Santala et al., 2003). 
Ca 19-9 tumor marker can be found elevated is 
elevated in up to 35% of patients with endometrial cancer.
A previous study of Cerchi et al. demonstrated that the 
combination of CA 125 and CA 19.9 offered interesting 
results for post-treatment surveillance showing a high 
sensitivity (83.3%) for the detection of recurrence, with 
only 12.8% of false positive cases (Cherchi et al., 1999).
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Despite the correlation between HE4 and lymph node 
involvement remains controversial, its measurement could 
afford additional tool for the choice of lymphadenectomy, 
improving overall patient management (Zanotti et al., 
2012; Angioli et al., 2013) (Figure 1).
Ovarian Cancer  
Though rare, accounting for more than 3% of all 
cancers in women , epithelial ovarian cancer (EOC) is 
the leading cause of gynecological cancer related death 
(Siegel et al., 2016).
More than 70 % of patients present  advanced tumor 
stage at diagnosis with widespread intra-peritoneal or 
distant metastases due to the lack of early symptoms to 
guide timely image-driven investigations (Modugno et al., 
2012; Marcus et al., 2014). The proper choice of treatment 
for ovarian cancer depends on accurate staging, in order to 
distinguish patients for whom primary surgery is unlikely 
to be successful.
Standard treatment includes aggressive surgery 
followed by platinum- and taxane-based chemotherapy. 
Patients with not completely resectable disease undergo to 
neoadjuvant chemotherapy followed by interval surgery.
Ovarian cancer imaging 
Characterize the nature of the ovarian masses is the 
first goal of diagnostic imaging in the clinical setting of 
EOC.
TVU is the primary imaging technique in ovarian 
cancer especially if carried out by an experienced 
sonographer allowing an accurate characterization of 
about 90% of adnexal masses. 
Morphology on TVU combined with Doppler 
waveform analysis are the most important  features to be 
considered for an accurate risk assessment of  adnexal 
lesions (Cramer et al., 2011).
In addition, TVU is considered the best tool for ovarian 
cancer screening in  patients at increased risk for ovarian 
carcinoma based either on their genetic profile or on 
serum markers (Manganaro et al., 2012a ; Manganaro et 
al., 2012b).
In addition Ca 19-9 was found to correlate with 
shortened survival in univariate analyses, but no 
significance could be established in multivariate analyses 
(Lo et al., 1997). 
However several studies demonstrated that CA19-9 
has limited prognostic value and is not usually part 
of routine examinations. 
Loco-regional tumor spread is a  negative prognostic 
factor for all endometrial cancer types in terms of disease 
free survival and mortality. Nevertheless Chen et al., 
(2011) suggested that elevated  preoperative CA 125 
level of  endometrial cancer patients correlated with the 
presence of lympho-vascular invasion suggesting that 
pre-operative CA125 levels may be considered a useful 
prognostic tool in endometrial cancer management.
Recently an increasing interest has been reported 
in literature on human epididymis protein 4 (HE4) 
demonstrating to be a useful clinical marker with 
high sensitivity and specificity even at early stage of 
endometrial cancer .
Moore et al., (2012) first reported elevated serum HE4 
levels in all stages of disease, with a better sensitivity 
compared to CA125 also  in the early stages . In addition 
HE4 levels seems to be related to the disease stage 
(Steffensen et al., 2011; Huhtinen et al., 2009).
In contrast, Ylmaz et al., (2016) contradicted the 
previous results of Moore’s study, founding no significant 
relation between HE-4 level and the tumor stage and 
suggesting a better sensitivity and specificity in terms 
of diagnosis with the combined use of HE4 and CA125. 
In addition in this paper no statistical relation between 
preoperative CA 125 and HE4 levels and the depth of 
the myometrial invasion detected at MR imaging was 
reported. 
However, Saarelainen et al., (2013) described  a 
statistically significant correlation between HE4 levels 
and metastases (p = 0.001), deep myometrial invasion (p 
< 0.001), and histologic grade (p = 0.012). 
According to international guidelines, in presence of 
deep MI, lymphadenectomy must be performed for the 
increased risk of lymph node metastasis. 
Figure 1. Endometrial Cancer Checklist, a Proposal for 
a Correct Patients Diagnosis, Staging and Follow-up. 
TVU, Transvaginal Ultrasound; MRI, Magnetic 
Resonance Imaging; CECT, Constrast Enhanced 
Computed Tomography; PET/CT, Positron Emission 
Tomography - Computed Tomography.
Figure 2. Ovarian Cancer Checklist, a Proposal for a 
Correct Patients Diagnosis, Staging and Follow-up. 
TVU, Transvaginal Ultrasound; MRI, Magnetic 
Resonance Imaging; CECT, Constrast Enhanced 
Computed Tomography; PET/CT, Positron Emission 
Tomography - Computed Tomography.
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The IOTA group proposed a mathematical model, the 
so-called ADNEX (the assessment of different neoplasia 
in the adnexa), to predict the risk that an ovarian mass 
is benign, borderline, stage I, stages II-IV or metastatic 
(Spencer et al., 2010). 
The reported diagnostic performance of ADNEX in 
differentiating between benign and malignant masses was 
0.937 (95% CI: 0.915-0.954) when CA125 was included, 
and 0.925 (95% CI: 0.902-0.943) when CA125 was 
excluded (Freydanck et al., 2012) . 
According to the literature about 8% of adnexal 
masses detected by sonography remains indeterminate 
at adnexal sonographic investigation. 
In these cases Magnetic Resonance Imaging (MRI) 
has maximal diagnostic and therapeutic impact resolving 
most of these uncertainties. 
The staging of EOC include the evaluation peritoneal 
dissemination, lymph-node involvement and parenchymal 
metastasis . Currently CT or MRI are used in this context .
Computed Tomography, is the imaging modality of 
choice for staging ovarian cancer but also for treatment 
follow-up, according to the European Society of 
Urogenital Radiology and the American College of 
Radiology guidelines for ovarian cancer staging and 
follow up, ensuring reproducibility of the results for future 
comparison in a short examination time with a reported 
accuracy of about 92%-97% (Alt, 2011; Hynninen et al., 
2013). 
In particular, the development of multidetector CT 
(MDCT) has improved the diagnostic ability of this 
imaging technique to depict s more clearly and directly 
intra-abdominal lesion.
MDCT has the advantages of having thinner sections 
and multiplanar reformations, providing more accurate 
preoperative staging and planning. 
MRI ,thanks to the higher soft-tissue contrast has 
some advantages for the evaluation of the local tumor 
spread the pelvis, and can be used in situations where CT 
is contraindicated.
In addition DCE-MRI is very accurate in detecting 
recurrent peritoneal ovarian cancer implants showing 
values of Sensitivity (90%) and specificity (100%).
However, in case of small and diffuse implants of 
carcinomatosis (<0.5 cm) and lymph-nodes with largest 
diameter less than 1 cm, CT and MRI could underestimate 
disease extent.
PET/CT has improved the accuracy of staging ovarian 
carcinoma (Hynninen et al., 2013). However its role in 
EOC staging is still controversial while it is considered 
more accurate than CT alone  in detecting tumor recurrence 
(sensitivity = 95–97% , specificity = 80–100%) (Addley 
et al., 2010). Furthermore, integrated FDG PET/CT is 
useful specifically in optimizing the treatment plan and 
it might play an important role in treatment stratification 
in the future (Lee et al., 2015).
Ovarian cancer biomarkers
The current reference biomarker for ovarian cancer 
detection is CA125 which it is considered also a prognostic 
tool for the detection of disease recurrence after surgery 
and adjuvant chemotherapy (Bilici et al., 2010; Engelen 
et al., 2006; Sturgeon et al., 2011; Anastasi et al., 2013). 
However, CA125 antigen is not elevated in most 
primary ovarian mucinous neoplasms . In primary ovarian 
mucinous tumors, CA19-9 antigen is used as a marker 
instead (Cho et al., 2014).
Terzic et al., (2014) in their series including 358 
consecutive patients found that the  positive rate of Ca 
125, Ca 19-9, Ca 15-3, and CEA in serous tumors was 
57.9, 7.9, 7.9 and 15.8%, respectively while for mucinous 
tumors was 31.8, 40.9, 27.3 and 40.9 %.
In the last few years human epididymis protein 
4 (HE4) has emerged as an important biomarker in 
differential diagnosis, early detection, prognosis and 
monitoring the response to chemotherapy of EOC. HE4 
is commonly overexpressed both in the early stage and 
in the recurrence of disease and it has been demonstrated 
that HE4 serum levels are not affected by the menstrual 
cycle, oral contraceptive use or endometriosis (Granato 
et al., 2012; Anastasi et al., 2010a; Anastasi et al., 2010; 
Granato et al., 2015).
The suggestion that HE4 is a good indicator for the 
remission from the disease was recently reported by 
follow-up studies, in which it was shown that the values 
of HE4 correlated with the clinical response to treatment 
or remission from the disease, as documented by CT 
imaging (Midulla et al., 2012).
It is important to note that HE4 serum levels combined 
with MDCT may improve the monitoring management of 
women affected by ovarian cancer (Anastasi et al., 2017).
Recent investigations suggested also a potential role 
of Gal-3 in EOC carcinogenesis.
Interestingly, it has also been suggested a strong 
correlation between high levels of Gal-3 and MDCT 
imaging findings of disease progression in patients with 
recurrent EOC (Wu et al., 2014). 
In the recent years, research has focused on new 
biomarkers such as mesothelin, inhibin, osteopontin and 
Ca72.4: the benefits of these markers remain unclear, and 
even if sensitivity is increased, specificity is sub-optimal 
(Walentowicz et al., 2014; Tilli et al., 2014). 
The expression of mesothelin in ovarian tissue 
correlated to chemotherapy resistance and poor prognosis 
Figure 3. Cervical Cancer Disease Progression and 
Diagnostic Workup. US, Ultrasound; MRI, Magnetic 
Resonance Imaging; CECT, Constrast Enhanced 
Computed Tomography; PET/CT, Positron Emission 
Tomography - Computed Tomography.
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suggesting a role for mesothelin in diagnosis and disease 
staging (Tilli et al., 2014).
It has been validated that the alteration of 
the inhibin/activin pathway may contribute to the 
development of epithelial ovarian cancer and high levels 
of inibin A are associated to a poor prognosis and a low 
survival at 5 years (Tilli et al., 2011).
Osteopontin enhances proliferation, migration and 
invasion of ovarian cancer cells but the role of this 
glycoprotein to discriminate malignant and benign ovarian 
tumors has not been sufficiently elucidated (Tilli et al., 
2014; Tilli et al., 2011).
Serum biomarker CA72.4 has also been shown 
to be elevated in EOC: it is slightly increased also in 
benign conditions but is not affected by pregnancy or the 
menstrual period (Lenhard et al., 2009).
However, according to the current guidelines 
measurement of serum CA125 antigen remains the gold 
standard in the follow-up EOC (Lenhard et al., 2009; 
Moore et al., 2012; Park et al., 2011) and some authors 
have demonstrated the important role of the biomarker 
CA72.4 combined with CA125 as a predictive factor of 
recurrence (Figure 2).
Discussion
Cervical Cancer 
Cervical cancer is the third most common gynecologic 
malignancy and the fourth leading cause of death in 
women worldwide, with an estimated global incidence 
of 470,000 new cases per-year (Darlin et al., 2014). 
The major risk-factor for developing cervical cancer is 
infection with high-risk human papillomavirus that lead 
to over-expression of two oncogenes (E6 and E7) related 
to transformation of neoplastic cells ( Cattani et al., 2009).
Although effective and prevention programs has been 
introduced about 30% of patients present an advanced 
stage at diagnosis and 30-50% of them relapse in the 
first 5-years after primary treatment (Wagner et al., 
2013). Proper staging is essential because patients at 
an early stage of disease (stage IA, IB1, IIa1) can be 
treated surgically, while surgery remains controversial 
in patients with locally advanced cervical carcinoma 
(IIb and beyond ), which are usually treated with 
neoadjuvant chemo-radiotherapy (Kato et al., 2015; 
Tangjitgamol et al., 2014).
Cervical cancer imaging 
In 2009, the International Federation of Gynecology 
and Obstetrics undertook a review of the clinical staging 
of cervical cancer, which recommended  the use of modern 
imaging methods in evaluating these significant prognostic 
factors (Kato et al., 2015). The American College of 
Radiology doesn’t recommend US for assessing the extent 
of cervical cancer (Siegel et al., 2012) However , recently, 
in Literature there is a crescent interest about the value of 
ultrasound examination for disease  assessment (Chiappa 
et al., 2015) Fisherova et al., (2008) examinated 95 with 
proven cervical cancer and found an accuracy of US of 
93.7% (95% CI 86.8 to 97.6), with a sensitivity of 93.4% 
(95% CI 85.3 to 97.8), and specificity of 94.7% (95% CI 
73.9 to 99.8) in detecting tumor lesions.
Similar results were obtained by Testa et al (Accuracy 
93%, 95% CI 84 to 97) who carried out TVU examination 
in 75 patients with early-stage disease and demonstrated 
that ultrasound was able to detect the presence of the 
tumor, deep stromal tumor invasion and infiltrated 
parametria (Testa et al., 2009).
However,US is not able to correctly assess lymph 
nodes involvement showing very low low accuract 
(arounding 38–43%.) if compared to other imaging 
methods(Pálsdóttir et al., 2015). 
MRI is the most reliable imaging modality for staging, 
treatment planning and follow-up of cervical cancer with 
reported values of sensitivity up to 100% in evaluating 
the parametrial infiltration, the degree of longitudinal 
extension and the bladder and rectal infiltration with 
an overall diagnostic accuracy values of about 93% 
(Kraljević et al., 2013). 
High resolution T2-weighted imaging is the mainstay 
for tumor detection. The high T2 signal of cervical lesions 
enables its differentiation from the normal cervical stroma 
that presents low T2 signal .
MRI is crucial for evaluating parametrial involvement 
(FIGO IB) that precludes surgical treatment, with reported 
accuracy values ranging from 88%-97%, significantly 
higher compared to clinical examination (Bourgioti et 
al., 2016).
More recently, DWI sequences has been implemented 
to MRI protocols for cervical cancer staging due to 
an excellent tissue contrast between neoplastic and 
non-neoplastic tissues . DWI are also able to distinguish 
residual tumor from fibrosis, especially in  patients 
previous treated with chemo-radiotherapy (Kuang et 
al., 2015; Bollineni et al. 2015). Park et al., (2014)
demonstrated that tumor ADC on MRI was an independent 
predictors of pathologic parametrial infiltration.
It has also been suggested that the ADC values 
may reflect the biologic heterogeneity of tumors thus 
providing information regarding its behavior , subtype 
characterization and cancer treatment response. In addition 
Nakamura et al., (2012) showed that ADC values were an 
independent prognostic factor for disease free survival 
after radical hysterectomy.
More recently, several studies emphasized the 
importance of MRI in predicting response to neoadjuvant 
chemotherapy. Indeed the  reconstitution of the normal 
signal hypointensity of stromal ring, on T2-dependent 
images, combined with DWI features are the most 
important signs of macroscopic response to treatment with 
a negative predictive value of 97% (Addley et al., 2010). 
PET-CT has been recently introduced into clinical 
practice and has been demonstrated to be useful in the 
staging of cervical cancer and superior to either CT or 
MRI in the detection of nodal disease. Particuarly ,a recent 
meta-analysis based on 67 Studies showed that PET or 
PET/CT has the highest specificity, and DWI-MRI has the 
highest sensitivity in detecting the lymph nodes metastases 
in patients with cervical Cancer (AUC of DWI-MRI 0.92 
and PET or PET/CT 0.90 compared with CT 0.83) ( Liu 
et al., 2017). Surveillance of women previously treated 
for cervical cancer remains problematic. PET-CT is 
et al
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recommanded  in selected cases as surveillance method 
after treatment for advanced-stage cervical cancer with 
reported value of sensitivity and specificity of 91% and 
94%, respectively (Ding et al., 2014).
Cervical cancer biomarkers
Today there are not validated biomarkers for the 
diagnosis, prognosis and follow-up of patients affected 
by cervical cancer. Increased serum squamous cell 
carcinoma antigen (SCC-Ag) levels have been observed 
in the majority of cervical squamous cell carcinomas. The 
SCC-Ag is normally expressed by basal and parabasal 
layers of normal squamous epithelium, but is found to be 
overexpressed in epithelia of cancerous tissue including 
cervical cancer (Kato et al., 1996).
The clinical relevance of SCC-Ag in the management 
of cervical cancer is still controversial. According to 
some authors SCC evaluation during the follow-up do not 
improve the early detection of the recurrence . By contrary, 
some authors described that increased SCC-Ag levels have 
been shown to be related to the stage of the disease, size 
of the tumor, depth of the stromal, lymphoadenopaties 
(Gaarenstroom et al., 2000). 
Some authors demonstrated a linear correlation 
between CEA and stage of the disease suggesting its 
prognostic value in cervical cancer ( Borras et al., 1995).
Keratins, formerly known as cytokeratins, are the 
major epithelial-specific subgroup of intermediate filament 
proteins. CYFRA21-1, a fragment of cytokeratin- 19 is 
expressed in normal epithelium and in carcinomas of 
the uterine cervix. To date, a number of studies have 
investigated the diagnostic accuracy of CYFRA21-1 for 
cervix cancer, but the results have been controversial. 
Suzuki et al. have been demonstrated a correlation 
between high Cyfra 21-1 levels and stage or recurrence 
of the disease, suggesting the use of this biomarker for the 
monitoring the outcome of patients affected by cervical 
cancer (Suzuki et al., 2000). 
By contrary, Gaarenstroom et al., (2000) reported that 
increased CYFRA21-1 levels were strongly related to 
tumor burden, but insufficiently reliable for identifying 
patients at risk of the presence of lymph node metastases 
or parametrial involvement. In summary SCC-Ag, CEA 
and Cyfra 21-1 cannot be considered good markers for 
prognosis and follow-up of cervical cancer, more accurate 
and reliable diagnostic methods/biomarkers should be 
discovered (Figure 3).
Vulvar Cancer 
Vulvar cancer (VC)  is a rare malignancy accounting 
for about 5% of cancers of the female genital tract and 
most often occurs in older women (Hiniker et al., 2013).
About 90% of vulvar carcinomas are squamous cell 
cancers and lesions are multifocal in about 5% of cases.
The labia majora are involved in about 50% of cases 
followed by labia minor, mons pubis, clitoris, Bartholin 
glands, and perineum (Barton et al., 2003). 
The overall incidence of vulvar cancer has risen over 
the last decade, probably because of an increase in human 
papilloma virus (HPV) infections (Viens et al., 2016)
Vulvar cancer imaging 
The diagnosis of vulvar carcinoma is usually made 
by clinical examination. Imaging plays an important role 
in management of vulvar carcinoma, especially locally 
advanced disease.
US is often used to perform image-guided biopsy 
procedures.
MRI is crucial for locoregional staging allowing to 
assess the involvement of adjacent structures (e.g., the 
anal sphincter, urethra, or vaginal wall) and pelvic nodal 
involvement thus helping to accurately plan the extent of 
surgery. In addition MRI can help in evaluating the extent 
of the local recurrence occurring 
In about 30–50% of patients within the first 2 years 
(Griffin et al., 2008).
Vulvar carcinoma spreads primarily by local extension 
via the lymphatic system while hematogenous spread is 
uncommon. The lymph node status has been identified 
as the most important prognostic factor in patients with 
vulvar cancer (Gonzalez et al., 2007). 
CT provides information on the presence of pelvic 
lymphadenopathy and distant metastases with a sensitivity 
and specificity of 58% and 75%, respectively (Land et 
al., 2006).
Cohn et al., (2002) evaluating the role of PET/CT in 
detecting groin lymphadenopathy in locally advanced 
vulvar cancer, before nodal dissection and  found a 
sensitivity of 80%, specificity of 90%, positive predictive 
value of 80%, and negative predictive value of 90%.
Vulvar cancer biomarkers 
Few biological markers have demonstrated clinical 
value for the management of vulvar cancer. Previous 
studies demonstrated that HPV and the surrogate 
biomarker p16 are associated with a less aggressive 
behaviour of vulvar cancer., while p53 positivity seems to 
be related with poor prognosis and significantly increased 
recurrence (Hay et al., 2016).
In conclusion several markers are currently employed 
in oncology practice  as indicators of particular tumor 
types; some of them being strictly tissue-specific. 
However, despite the high numbers of promising 
biomarkers proposed, none of these, used alone, achieve 
high diagnostic accuracy values. Recently imaging 
research has been focused on the possibility to determine 
functional tissue characteristics thus changing the 
diagnostic approach of radiologists which was previously 
based on morphologic and macroscopic tumor features 
thanks to different imaging methods such as DWI and 
PET. DWI has improved  the diagnostic accuracy of 
conventional magnetic resonance imaging, providing 
useful information about tumor cellularity while PET has 
been introduced in the diagnostic setting for its ability to 
assess tumor metabolism.
In conclusion despite these advances in imaging 
techniques and the discovery of new biological markers 
have provided significant improvement in the care of 
female cancer patients, further advancements are needed 
to improve patient care., a multimodal approach including 
the evaluation of serum tumor biomarkers combined with 
imaging techniques, seems to be the best strategy for 
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assessing tumor presence, spread, recurrence, and/or the 
response to treatment in female cancer patients. 
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